Articles tagged with Egfr Inhibitors
A rare inherited EGFR mutation is associated with a 25-fold increased risk of lung cancer in non-smokers. Carriers of the mutation are more than 60 times as likely to develop lung cancer as people without it.
A study published in JAMA finds that using different methods to estimate glomerular filtration rate (eGFR) can lead to significant discrepancies, particularly for those with chronic kidney disease. The findings suggest that cystatin C-based eGFR may be more accurate in predicting clinical outcomes.
The phase 3 FLAURA2 study shows that adding platinum-pemetrexed to osimertinib improves overall survival in patients with newly diagnosed EGFR-mutated advanced NSCLC. Median overall survival was 47.5 months, compared to 37.6 months with osimertinib alone.
Researchers have developed three-dimensional spheroid cultures that better replicate cell-cell interactions and nutrient gradients, leading to a greater understanding of tumour tissue behaviour and drug responses. The study highlights the importance of mimicking tumour architecture in testing cancer therapies.
A clinical trial found that LUT014, a topical BRAF inhibitor, significantly reduced the severity of acne-like skin rashes caused by targeted therapy for colorectal cancer. Patients who received LUT014 had improved quality of life and were able to continue receiving their cancer treatment with reduced side effects.
Scientists have found a way to effectively 'intercept' pancreatic cancer by targeting the KRAS and FGFR2 genes. This approach slows tumor formation and reduces the number of 'early versions' of cancer in the pancreas. Researchers believe this therapy could be a game-changer for patients with a family history of pancreatic cancer.
A phase 2 clinical trial found that a combination of two HER2 inhibitors was more effective and better tolerated than standard EGFR inhibitor-based therapy for patients with HER2-positive metastatic colorectal cancer. The study showed that the level of HER2 amplification in tumors played a key role in determining treatment outcomes.
Researchers designed a molecule, MTX-531, that impairs signaling drivers of cancer therapy resistance. In mouse models, MTX-531 led to tumor regressions in multiple head and neck cancers, showing a favorable toxicity profile.
Researchers found that GZ17-6.02 killed uveal melanoma cells by enhancing autophagy, inactivating key proteins, and reducing growth factors. The compound also interacted with doxorubicin and ERBB inhibitors to enhance tumor cell killing, suggesting potential as a single agent or combination therapy.
Researchers investigated combining Sacituzumab govitecan with platinum-based chemotherapeutics for triple-negative breast cancer, urinary bladder carcinoma, and small-cell lung carcinoma. The study showed additive to synergistic antitumor effects in vitro and in vivo, with improved outcomes in tumor-bearing animals.
Researchers at University at Buffalo propose a new approach to developing cancer drugs by determining the optimal placement of molecular linkers earlier in the process, reducing trial and error and increasing potency, according to a study published in Communications Chemistry.
Researchers highlight difficulties in targeting metastatic tumors and propose two- and three-drug combinations to achieve effective tumor control. They also emphasize the need for simultaneous blocking of primary driving oncogene, evolving resistance mechanism, and secondary survival pathway.
A novel three-drug combination of an HDAC inhibitor with two types of immunotherapy achieved a 25% overall response rate and 50% progression-free survival in women with advanced HER2-negative breast cancer. Patients with triple-negative breast cancer had a higher response rate, highlighting the need for further clinical evaluation.
Lung adenocarcinoma cells manipulate macrophage lipid metabolism to drive tumor progression. This exploitation of immune cells' metabolic pathways may be targeted with statins, improving lung cancer treatments.
Patients with heart failure treated with dapagliflozin experienced frequent initial estimated glomerular filtration rate declines, but without increased cardiovascular or kidney event risks. The study suggests that sodium-glucose cotransporter-2 inhibitors can be safely continued in patients experiencing eGFR decline.
Researchers at MUSC Hollings Cancer Center have identified new targets for treating breast cancer that has become resistant to hormone therapy and CDK4/6 inhibitors. By understanding the molecular mechanisms of resistance, the team has found potential solutions using epidermal growth factor receptors and PARP inhibitors.
Researchers found that a combination of AXL and EGFR inhibitors can suppress tumor growth and prevent relapse in patients with certain cancers. The study clarifies the novel regulatory mechanism by which AXL stimulates YAP via the EGFR-LATS1/2 axis.
Researchers found that BUB1 protein regulates EGFR signaling by reducing receptor internalization, which may lead to new therapeutic interventions for EGFR-driven cancers. The study also showed that BUB1 impacts receptor recycling and degradation, affecting signaling amplitude and duration.
Researchers at the University of Texas M. D. Anderson Cancer Center have identified CD70 as a novel therapeutic target for eliminating drug-resistant cancer cells in EGFR-mutant non-small cell lung cancer. CD70 targeting strategies showed significant anti-tumor activity, eliminating resistant cells in laboratory models.
A study published in Hepatology reveals that the EGFR protein plays a crucial role in the entry mechanism of hepatitis E virus into human hepatocytes. The researchers found that suppressing the activity of the EGFR protein significantly reduced cell infections, suggesting potential therapeutic applications for approved cancer drugs.
A study found that activation of the epidermal growth factor receptor (EGFR)-mediated signaling pathway is involved in lenvatinib resistance in thyroid cancer cells. Inhibition of EGFR by lapatinib therapy in combination with lenvatinib enhanced growth inhibitory effect and inhibited tumor growth more remarkably than monotherapy.
The study found an overall response rate of 32% across all patients with EGFR exon 20 mutations, varying depending on the location of the mutation. Near-loop insertions showed a 46% overall response rate, while far-loop insertions had no response rate.
Researchers have discovered that intestinal bacteria can lead to more severe adhesions after abdominal surgery. The study found that mesothelial cells and EGFR signaling play a crucial role in the formation of these adhesions. The findings suggest that targeting EGFR may be a potential approach to reducing adhesion risk.
Patients treated with pyrotinib plus capecitabine had a lower risk of death and longer progression-free survival compared to those receiving lapatinib plus capecitabine. Pyrotinib is an irreversible tyrosine kinase receptor inhibitor targeting HER2, EGFR, and HER4.
A phase Ib study found that combining sotorasib, a KRAS G12C inhibitor, with afatinib, a pan-ErbB tyrosine kinase inhibitor, showed antitumor activity in patients with KRAS-mutant non-small cell lung cancer. The combination demonstrated a high disease control rate and improved efficacy compared to prior therapies.
A study identifies four novel subgroups of EGFR mutations that predict drug response, offering a more accurate framework to match patients with targeted therapies. The findings reveal that certain mutations respond better to specific classes of TKIs, providing new clinical opportunities for approved treatments.
A study identifies three molecular subtypes in HNSCC, suggesting different therapy options for EGFR, CDK, and immunotherapy. Biomarkers like EGFR ligands and Rb phosphorylation status may help select patients for targeted treatments.
The BEACON CRC trial demonstrated a survival advantage for patients with chemo-refractory BRAF mutant CRC treated with the combination of BRAF inhibitor encorafenib and EGFR inhibitor cetuximab. PLX8394, a paradox-breaker BRAF inhibitor, showed comparable efficacy to encorafenib in reducing pathway reactivation.
A phase III study showed that the combination of encorafenib, binimetinib, and cetuximab significantly improved overall survival (9.0 months) and objective response rates compared to standard care. The treatment was well-tolerated, suggesting a potential paradigm shift in treating BRAF-mutant metastatic colorectal cancer.
Adding savolitinib to osimertinib yields clinical responses in patients with EGFR-mutant non-small cell lung cancer and MET-driven acquired resistance. The combination therapy demonstrates efficacy in a patient population for whom chemotherapy is the current primary treatment option.
Researchers at IRB Barcelona and Vrije Universiteit Brussel have identified camelid nanobodies effective against EGF, a growth factor dysregulated in cancer cells. These nanobodies could provide a potential treatment for patients developing resistance to existing EGFR inhibitors.
Researchers identified a pair of genes, EphB4 and ephrin-B2, that are silenced in healthy adult tissue but reactivated in tumors resistant to treatment. Adding an experimental inhibitor targeting these genes to existing therapies improved survival rates in mice models.
Research from MD Anderson Cancer Center suggests that chronic stress hormones can promote resistance to EGFR inhibitors in lung cancer patients. However, using beta blockers may slow or prevent this resistance, according to the study's findings.
A clinical trial found that adding vemurafenib to treatment with cetuximab and irinotecan significantly improved progression-free survival for patients with BRAF V600E mutation, from 2.0 months to 4.3 months. The study suggests combining BRAF inhibitors with EGFR inhibitors may be a more potent approach.
A phase III clinical trial suggests a potential new treatment for patients with advanced EGFR-positive non-small cell lung cancer. Dacomitinib delayed cancer growth by 5.5 months compared to gefitinib, but also caused more side effects.
This study explores the structural features of quercetin derivatives that inhibit EGFR protein in NSCLC cells. The researchers developed a pharmacophore model that identified key features, such as hydrogen bond acceptors and aromatic rings, which are associated with effective inhibition.
Researchers identified a molecular marker called Mig 6 that predicts longer survival among patients treated with two popular cancer drugs. The study found higher levels of Mig 6 in tumors that responded poorly to the drugs, while low levels were associated with prolonged survival.
Researchers identified a specific pattern of DNA modifications dependent on HPV presence that correlates with improved survival in patients with OPSCC. A new combination therapy for PEL was found to reactivate virus-induced cell lysis and induce cancer cell death, increasing mouse lifespan.
A new drug combination has shown promise in preventing head and neck cancer in high-risk patients. The combination of erlotinib and celecoxib was found to be more effective in inhibiting the growth of human SCCHN cell lines compared to either drug alone.
A recent study published in the Proceedings of the National Academy of Sciences reveals that a modification of the tumor suppressor gene PTEN is associated with resistance to glioblastoma treatments. The research suggests that targeting PTEN modification could lead to improved treatment outcomes for patients with glioblastoma.
Researchers discovered that combining EGFR inhibitors with Wnt pathway inhibition can improve the durability of lung cancer remission. The Wnt pathway allows lung cancer cells to escape from EGFR-targeted therapy, but disrupting this pathway could lengthen the usefulness of existing treatments.
Researchers have identified potential mechanisms to prevent drug-induced skin lesions in BRAF mutation-positive melanoma patients treated with current therapies. Next-generation BRAF inhibitors may also represent a novel single-agent treatment option, avoiding this side effect and extending treatment durability.
A Phase II study of the new-generation lung cancer drug PF-299 has shown impressive results in preventing disease progression when administered as a first-line treatment in patients with advanced disease. The study found that 85% of patients with EGFR mutations remained progression-free for at least nine months.
The TRUST study found that erlotinib significantly increased survival for patients with previously treated advanced NSCLC. Certain patient groups, such as adenocarcinoma, women, and Asian ethnicity, showed greater tumor responses to EGFR TK inhibitors.
Researchers at Fox Chase Cancer Center identified over 60 proteins necessary for cancer cells to survive with EGFR inhibitors, demonstrating a two-hit strategy that increases tumor cell death. This approach will open the door for future therapies and has already led to two clinical trials testing innovative drug combinations.
Knockdown of E2F1 gene significantly reduced the invasive potential of melanoma cells without affecting proliferation rates. EGFR expression was also decreased in E2F1-silenced cells, further supporting the role of E2F1 in cancer progression.
Researchers at Fox Chase Cancer Center have found that lung cancer patients who have progressed on a cetuximab-containing regimen may respond to erlotinib. The study suggests that patients who are no longer controlled by cetuximab can derive clinical benefit from erlotinib, offering an additional treatment option.
Three studies investigate how tumors respond to EGFR inhibitors, revealing the crucial role of BIM protein in triggering apoptosis. The findings suggest that induction of BIM may lead to a new way of treating tumors resistant to these drugs.
Researchers studied two lung cancer-derived EGFR mutants and found distinct differences in inhibitor binding, leading to overactivation of the enzyme. The study suggests that specific mutants have unique targets for inhibition, potentially reducing toxicity and increasing effectiveness.
A study published in Cancer Cell reveals that combining therapies targeting EGFR and Akt can improve treatment outcomes in tumor cells with PTEN mutations. The research demonstrates that BAD acts as a key switch integrating antiapoptotic effects of multiple pathways, providing new insights into combination therapy strategies.
A recent study found that bainiku-ekisu inhibits AngII-induced EGF receptor transactivation and ERK activation in vascular smooth muscle cells, suggesting its potential as a new therapeutic agent for cardiovascular diseases like hypertension and atherosclerosis.